BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 21918338)

  • 1. [Anti-RANKL antibody for the management of bone metastasis].
    Yoneda T
    Gan To Kagaku Ryoho; 2011 Sep; 38(9):1439-45. PubMed ID: 21918338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Anti-RANKL antibody for treatment of patients with bone metastasis from breast cancer].
    Takahashi S
    Gan To Kagaku Ryoho; 2012 Jan; 39(1):89-94. PubMed ID: 22241358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical development of anti-RANKL therapies for treatment and prevention of bone metastasis.
    Lipton A; Goessl C
    Bone; 2011 Jan; 48(1):96-9. PubMed ID: 20950721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of bone metastasis with anti-RANKL antibody].
    Chayahara N; Minami H
    Clin Calcium; 2011 Aug; 21(8):1217-22. PubMed ID: 21814028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of bone metastasis by denosumab, the human monoclonal neutralizing antibody to RANKL].
    Yoneda T
    Nihon Rinsho; 2012 Dec; 70(12):2165-71. PubMed ID: 23259391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The clinical merit of anti-RANKL antibody denosumab in prostate cancer].
    Akaza H; Tsukamoto T; Suzuki K; Namiki M; Ozono S; Naitodept S
    Gan To Kagaku Ryoho; 2012 Feb; 39(2):207-12. PubMed ID: 22333629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
    Henry DH; Costa L; Goldwasser F; Hirsh V; Hungria V; Prausova J; Scagliotti GV; Sleeboom H; Spencer A; Vadhan-Raj S; von Moos R; Willenbacher W; Woll PJ; Wang J; Jiang Q; Jun S; Dansey R; Yeh H
    J Clin Oncol; 2011 Mar; 29(9):1125-32. PubMed ID: 21343556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Involvement of RANKL/RANK pathway in bone metastasis in breast cancer].
    Yoneda T
    Clin Calcium; 2011 Aug; 21(8):1159-66. PubMed ID: 21814020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Mechanism and strategy for treatment of cancer metastasis to bone].
    Yoneda T
    Gan To Kagaku Ryoho; 2011 Jun; 38(6):877-84. PubMed ID: 21677475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Denosumab: benefits of RANK ligand inhibition in cancer patients.
    Lipton A; Jacobs I
    Curr Opin Support Palliat Care; 2011 Sep; 5(3):258-64. PubMed ID: 21826000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Denosumab for the prevention of skeletal-related events in patients with bone metastasis from solid tumor.
    Iranikhah M; Wilborn TW; Wensel TM; Ferrell JB
    Pharmacotherapy; 2012 Mar; 32(3):274-84. PubMed ID: 22392458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
    Dempster DW; Lambing CL; Kostenuik PJ; Grauer A
    Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RANKL inhibition in the treatment of bone metastases.
    Lipton A; Jun S
    Curr Opin Support Palliat Care; 2008 Sep; 2(3):197-203. PubMed ID: 18685421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Denosumab for the treatment of cancer therapy-induced bone loss and prevention of skeletal-related events in patients with solid tumors.
    Lipton A; Balakumaran A
    Expert Rev Clin Pharmacol; 2012 Jul; 5(4):359-71. PubMed ID: 22943116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Denosumab for the treatment of bone metastases in advanced breast cancer.
    Casas A; Llombart A; Martín M
    Breast; 2013 Oct; 22(5):585-92. PubMed ID: 23759273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
    Stopeck A; Rader M; Henry D; Danese M; Halperin M; Cong Z; Qian Y; Dansey R; Chung K
    J Med Econ; 2012; 15(4):712-23. PubMed ID: 22409231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic Potential of Denosumab in Patients With Lung Cancer: Beyond Prevention of Skeletal Complications.
    De Castro J; García R; Garrido P; Isla D; Massuti B; Blanca B; Vázquez J
    Clin Lung Cancer; 2015 Nov; 16(6):431-46. PubMed ID: 26264596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Denosumab for the management of bone disease in patients with solid tumors.
    Body JJ
    Expert Rev Anticancer Ther; 2012 Mar; 12(3):307-22. PubMed ID: 22192269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapeutic agents for disorders of bone and calcium metabolism--Denosumab, a fully human monoclocal antibody-targeting RANKL as a therapy for cancer-induced bone diseases].
    Mera K; Ito K
    Clin Calcium; 2007 Jan; 17(1):37-46. PubMed ID: 17211092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid.
    Martin M; Bell R; Bourgeois H; Brufsky A; Diel I; Eniu A; Fallowfield L; Fujiwara Y; Jassem J; Paterson AH; Ritchie D; Steger GG; Stopeck A; Vogel C; Fan M; Jiang Q; Chung K; Dansey R; Braun A
    Clin Cancer Res; 2012 Sep; 18(17):4841-9. PubMed ID: 22893628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.